PeriFlow Targets Capillary No-Reflow to Prevent Heart Damage
Even after a surgeon clears a blocked artery with a stent, the heart’s smallest vessels often remain constricted, causing tissue death. A study published in Nature introduces CLN-2501, a first-in-class capillary-selective vasodilator designed to force these vessels open and restore blood flow where current interventions fail.
Modern cardiology has long struggled with Capillary No-Reflow, a phenomenon where capillaries stay pathologically closed despite successful stent placement. Affecting a majority of STEMI patients, this condition leads to larger infarct sizes and increased heart failure risk. Dr. András Málnási-Csizmadia and his research team identified that myosin proteins drive these hypercontractions. By developing a myosin inhibitor, they created CLN-2501, which rapidly relaxes capillaries in preclinical models.
Harvard Medical School’s Dr. C. Michael Gibson noted that while stents revolutionized artery clearance, the lack of an effective treatment for downstream capillary blockage leaves many patients with poor outcomes. The drug’s developer, PeriFlow Therapeutics, is now advancing the candidate toward US clinical trials. Beyond heart attacks, this mechanism holds potential for treating ischemic stroke and acute kidney injury.
Comments (0)
No comments yet. Be the first!